^
BIOMARKER:

MET mutation

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET mutation
RCC
savolitinib
Sensitive: B - Late Trials
MET mutation
NSCLC
crizotinib
Sensitive: C2 – Inclusion Criteria
MET mutation
RCC
cabozantinib capsule
Sensitive: C2 – Inclusion Criteria
MET mutation
RCC
crizotinib
Sensitive: C2 – Inclusion Criteria
MET mutation
Gastric Cancer
TPX-0022
Sensitive: C3 – Early Trials
MET mutation
RCC
c-MET inhibitor
Sensitive: C3 – Early Trials
MET mutation
RCC
sunitinib
Sensitive: C3 – Early Trials
MET mutation
RCC
everolimus
Sensitive: C3 – Early Trials
MET mutation
RCC
GSK1363089
Sensitive: C3 – Early Trials
MET mutation
NSCLC
MTI-31
Sensitive: D – Preclinical